Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,longTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,IMMPF,9574849.0,138200992,724285,,-2069706,,-1950293,361276,32230,-1365998,-1365998,,-166040,,,,-119412,32230,1398229,0,-703708,,-1950293,-1950293,79947.0,27237329.0,1260878.0,9654796.0,404095.0,90267.0,10915674.0,25022130.0,1016635.0,-45966347.0,3361684.0,578583.0,5862057.0,1260878.0,6623.0,3361684.0,411606.0,7427280.0,2418258.0,481929.0,418072.0,,-125000,190738,-293394,-295652,2804169,3250000,1574077,-109,-936590,63525,-29868,68,-150178,759372,-138525,6166402.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.1025,1629735307,0.0,0.1025,0.1025,0.1025,5000,0,IMMUPHARMA,PRE,us_market,0.0,0.1025 - 0.1025,0.1025,0.0,0.0,0,0,finmb_25990093,Other OTC,ImmuPharma plc,GBP,1230,0,0.020499997,0.24999996,0.082 - 0.22,-0.1175,-0.53409094,0.082,0.22,-0.36775705,0.17392594,-0.07142594,-0.4106687,-0.048,0.039,0.16212122,-0.059621222,19311410,2.628205,15,America/New_York,EDT,-14400000,False,False,1.26,,,0.22,0.082,0.1621,0.1739,1.23k,,138.2M,,174.89M,40.04%,18.74%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-4,412.70%",-41.79%,-91.93%,126.67k,0.00,-2.60%,126.67k,-5.42M,-6.86M,-0.0480,,5.86M,0.02,641.84k,6.65,5.89,0.04,-3.33M,-1.48M,Value,EC1A 7BL,,18,"ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer.  The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.",London,1609372800,United Kingdom,http://www.immupharma.co.uk,86400,1 Bartholomew Close,
t-1,IMMPF,9574849.0,138200992,724285,,-2069706,,-1950293,361276,32230,-1365998,-1365998,,-166040,,,,-119412,32230,1398229,0,-703708,,-1950293,-1950293,79947.0,27237329.0,1260878.0,9654796.0,404095.0,90267.0,10915674.0,25022130.0,1016635.0,-45966347.0,3361684.0,578583.0,5862057.0,1260878.0,6623.0,3361684.0,411606.0,7427280.0,2418258.0,481929.0,418072.0,,-125000,190738,-293394,-295652,2804169,3250000,1574077,-109,-936590,63525,-29868,68,-150178,759372,-138525,6166402.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.1025,1629735307,0.0,0.1025,0.1025,0.1025,5000,0,IMMUPHARMA,PRE,us_market,0.0,0.1025 - 0.1025,0.1025,0.0,0.0,0,0,finmb_25990093,Other OTC,ImmuPharma plc,GBP,1230,0,0.020499997,0.24999996,0.082 - 0.22,-0.1175,-0.53409094,0.082,0.22,-0.36775705,0.17392594,-0.07142594,-0.4106687,-0.048,0.039,0.16212122,-0.059621222,19311410,2.628205,15,America/New_York,EDT,-14400000,False,False,1.26,,,0.22,0.082,0.1621,0.1739,1.23k,,138.2M,,174.89M,40.04%,18.74%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-4,412.70%",-41.79%,-91.93%,126.67k,0.00,-2.60%,126.67k,-5.42M,-6.86M,-0.0480,,5.86M,0.02,641.84k,6.65,5.89,0.04,-3.33M,-1.48M,Value,EC1A 7BL,,18,"ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer.  The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.",London,1609372800,United Kingdom,http://www.immupharma.co.uk,86400,1 Bartholomew Close,
t-2,IMMPF,5376348.0,138200992,462132,,-1553382,,-1479671,521173,31104,-1428718,-1428718,,-166040,,,,-73712,31104,1459821,0,-124664,,-1479671,-1479671,502062.0,27122305.0,2103359.0,5878410.0,,,7981769.0,18301093.0,1774001.0,-42195936.0,2650948.0,760011.0,2713903.0,504564.0,267023.0,2650948.0,276302.0,4797911.0,1645483.0,310007.0,237541.0,1598795.0,-125000,-133775,8793,953475,1381008,750000,674532,12842,-728111,21952,50413,-4258,-322468,867641,-41620,4293347.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.1025,1629735307,0.0,0.1025,0.1025,0.1025,5000,0,IMMUPHARMA,PRE,us_market,0.0,0.1025 - 0.1025,0.1025,0.0,0.0,0,0,finmb_25990093,Other OTC,ImmuPharma plc,GBP,1230,0,0.020499997,0.24999996,0.082 - 0.22,-0.1175,-0.53409094,0.082,0.22,-0.36775705,0.17392594,-0.07142594,-0.4106687,-0.048,0.039,0.16212122,-0.059621222,19311410,2.628205,15,America/New_York,EDT,-14400000,False,False,1.26,,,0.22,0.082,0.1621,0.1739,1.23k,,138.2M,,174.89M,40.04%,18.74%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-4,412.70%",-41.79%,-91.93%,126.67k,0.00,-2.60%,126.67k,-5.42M,-6.86M,-0.0480,,5.86M,0.02,641.84k,6.65,5.89,0.04,-3.33M,-1.48M,Value,EC1A 7BL,,18,"ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer.  The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.",London,1609372800,United Kingdom,http://www.immupharma.co.uk,86400,1 Bartholomew Close,
t-3,IMMPF,5376348.0,138200992,462132,,-1553382,,-1479671,521173,31104,-1428718,-1428718,,-166040,,,,-73712,31104,1459821,0,-124664,,-1479671,-1479671,502062.0,27122305.0,2103359.0,5878410.0,,,7981769.0,18301093.0,1774001.0,-42195936.0,2650948.0,760011.0,2713903.0,504564.0,267023.0,2650948.0,276302.0,4797911.0,1645483.0,310007.0,237541.0,1598795.0,-125000,-133775,8793,953475,1381008,750000,674532,12842,-728111,21952,50413,-4258,-322468,867641,-41620,4293347.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.1025,1629735307,0.0,0.1025,0.1025,0.1025,5000,0,IMMUPHARMA,PRE,us_market,0.0,0.1025 - 0.1025,0.1025,0.0,0.0,0,0,finmb_25990093,Other OTC,ImmuPharma plc,GBP,1230,0,0.020499997,0.24999996,0.082 - 0.22,-0.1175,-0.53409094,0.082,0.22,-0.36775705,0.17392594,-0.07142594,-0.4106687,-0.048,0.039,0.16212122,-0.059621222,19311410,2.628205,15,America/New_York,EDT,-14400000,False,False,1.26,,,0.22,0.082,0.1621,0.1739,1.23k,,138.2M,,174.89M,40.04%,18.74%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,"-4,412.70%",-41.79%,-91.93%,126.67k,0.00,-2.60%,126.67k,-5.42M,-6.86M,-0.0480,,5.86M,0.02,641.84k,6.65,5.89,0.04,-3.33M,-1.48M,Value,EC1A 7BL,,18,"ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer.  The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.",London,1609372800,United Kingdom,http://www.immupharma.co.uk,86400,1 Bartholomew Close,
